TLPPF - Telix Pharmaceuticals Limited reports FY results
- Telix Pharmaceuticals press release ( OTCPK:TLPPF ): FY net loss after tax A$104.1M.
- Adjusted earnings before tax, interest, depreciation and amortisation -A$67.8M.
- Revenue of A$160.1M (vs. A$7.6M Y/Y).
- Cash and cash equivalents of A$116.3M as at 31 December 2022.
For further details see:
Telix Pharmaceuticals Limited reports FY results